Open AccessLactobacillus bulgaricus inhibits colitis-associated cancer via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium sulfate model
Author(s) -
Denise Sayuri Calheiros da Silveira,
Luciana Chain Veronez,
Luís Carlos Lopes-Júnior,
Elen Anatriello,
Mariângela Ottoboni Brunaldi,
Gabriela Pereira-da-Silva
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i43.6782
Subject(s) - azoxymethane , colitis , inflammation , lactobacillus , cancer , colorectal cancer , medicine , intestinal mucosa , chemistry , cancer research , immunology , biochemistry , fermentation
Colitis-associated cancer (CAC) accounts for 2%-3% of colorectal cancer (CRC) cases preceded by inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. Intestinal microbiota has been reported to play a central role in the pathogenesis of IBD and CAC. Recently, numerous prebiotics and probiotics have being investigated as antitumor agents due to their capacity to modulate inflammatory responses. Previous studies have indicated that lactic acid bacteria could be successfully used in managing sporadic CRC, however little is known about their role in CAC.